Methotrexate is a cornerstone treatment for rheumatoid arthritis, but it's unpredictable. Some people get great relief, others struggle with side effects, and doctors can't always tell who will be who. A new analysis of data from 2,345 patients suggests part of the answer might be written in our genes.
The research looked at two specific variations in a gene called FPGS. It found that people who carried certain versions of these gene variations were more likely to have methotrexate work well for them. But here's the catch: those same gene variations were also consistently linked to a higher risk of experiencing toxicity, or harmful side effects, from the drug. The connection was strongest in patients of Asian and European descent, and wasn't seen in other groups studied.
This is a meta-analysis, which means it pools results from previous observational studies. It shows a clear association, but it cannot prove that the genes cause the different outcomes. It's a strong clue that our genetics play a role in this drug's tricky balance of benefit and risk. The findings support the idea of one day using genetic information to guide treatment, but that day isn't here yet—more research is needed to understand how to use this information safely and effectively for all patients.